Humacyte Statistics
Total Valuation
Humacyte has a market cap or net worth of $134.70 million. The enterprise value is $149.55 million.
Important Dates
The last earnings date was Friday, March 27, 2026, before market open.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Humacyte has 222.02 million shares outstanding. The number of shares has increased by 33.49% in one year.
| Current Share Class | 222.02M |
| Shares Outstanding | 222.02M |
| Shares Change (YoY) | +33.49% |
| Shares Change (QoQ) | +17.98% |
| Owned by Insiders (%) | 4.26% |
| Owned by Institutions (%) | 25.42% |
| Float | 190.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 66.09 |
| Forward PS | 4.78 |
| PB Ratio | 37.66 |
| P/TBV Ratio | 43.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 73.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.69, with a Debt / Equity ratio of 21.02.
| Current Ratio | 3.69 |
| Quick Ratio | 2.77 |
| Debt / Equity | 21.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -52.82% |
| Return on Invested Capital (ROIC) | -137.79% |
| Return on Capital Employed (ROCE) | -109.64% |
| Weighted Average Cost of Capital (WACC) | 15.10% |
| Revenue Per Employee | $11,076 |
| Profits Per Employee | -$221,918 |
| Employee Count | 184 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.05% in the last 52 weeks. The beta is 2.10, so Humacyte's price volatility has been higher than the market average.
| Beta (5Y) | 2.10 |
| 52-Week Price Change | -69.05% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 30.43 |
| Average Volume (20 Days) | 10,131,961 |
Short Selling Information
The latest short interest is 40.68 million, so 18.32% of the outstanding shares have been sold short.
| Short Interest | 40.68M |
| Short Previous Month | 38.16M |
| Short % of Shares Out | 18.32% |
| Short % of Float | 21.31% |
| Short Ratio (days to cover) | 9.53 |
Income Statement
In the last 12 months, Humacyte had revenue of $2.04 million and -$40.83 million in losses. Loss per share was -$0.26.
| Revenue | 2.04M |
| Gross Profit | -76.37M |
| Operating Income | -107.44M |
| Pretax Income | -40.83M |
| Net Income | -40.83M |
| EBITDA | -100.09M |
| EBIT | -107.44M |
| Loss Per Share | -$0.26 |
Full Income StatementBalance Sheet
The company has $50.50 million in cash and $65.35 million in debt, with a net cash position of -$14.85 million or -$0.07 per share.
| Cash & Cash Equivalents | 50.50M |
| Total Debt | 65.35M |
| Net Cash | -14.85M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 3.11M |
| Book Value Per Share | 0.02 |
| Working Capital | 49.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$105.04 million and capital expenditures -$884,000, giving a free cash flow of -$105.93 million.
| Operating Cash Flow | -105.04M |
| Capital Expenditures | -884,000 |
| Depreciation & Amortization | 7.35M |
| Net Borrowing | 36.98M |
| Free Cash Flow | -105.93M |
| FCF Per Share | -$0.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -5,271.69% |
| Pretax Margin | -2,003.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Humacyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.49% |
| Shareholder Yield | -33.49% |
| Earnings Yield | -30.31% |
| FCF Yield | -78.64% |
Analyst Forecast
The average price target for Humacyte is $6.44, which is 961.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.44 |
| Price Target Difference | 961.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 243.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Humacyte has an Altman Z-Score of -9.48 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.48 |
| Piotroski F-Score | 2 |
